日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression

传统中药复方Rocaglamide通过抑制p53表达保护非恶性原代细胞免受DNA损伤引起的毒性

M S Becker, P Schmezer, R Breuer, S F Haas, M A Essers, P H Krammer, M Li-Weber

Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression

Rocaglamide 通过抑制 c-FLIP 表达的翻译来打破 HTLV-1 相关成人 T 细胞白血病/淋巴瘤中的 TRAIL 耐药性

M Bleumink, R Köhler, M Giaisi, P Proksch, P H Krammer, M Li-Weber

Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1

汉黄芩素和相关的天然黄酮是 CDK9 的抑制剂,可通过抑制 Mcl-1 的转录来诱导癌细胞凋亡

G Polier, J Ding, B V Konkimalla, D Eick, N Ribeiro, R Köhler, M Giaisi, T Efferth, L Desaubry, P H Krammer, M Li-Weber

Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression

Rocaglamide 通过差异调节 CD95L 和 c-FLIP 表达,使白血病 T 细胞对活化诱导的细胞死亡敏感

J Y Zhu, M Giaisi, R Köhler, W W Müller, A Mühleisen, P Proksch, P H Krammer, M Li-Weber

A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs

CD95配体启动子中一种新型AP-1元件是抗癌药物治疗诱导肝细胞癌细胞凋亡所必需的。

Eichhorst, S T; Müller, M; Li-Weber, M; Schulze-Bergkamen, H; Angel, P; Krammer, P H